Fernández-Metzler, Carmen
Ackermann, Brad
Garofolo, Fabio
Arnold, Mark E.
DeSilva, Binodh
Gu, Huidong
Laterza, Omar
Mao, Yan
Rose, Mark
Vazvaei-Smith, Faye
Steenwyk, Rick
Article History
Received: 14 February 2022
Accepted: 31 March 2022
First Online: 9 May 2022
Declarations
: The views expressed in this article are those of the authors and do not reflect the official policy of the authors’ organizations.
: B.L.A. is employed by Ely Lilly and Company; M.E.A. is employed by Labcorp Drug Development; B.deS. and H.G. are employed by Bristol-Myers Squibb; C.F-M. is employed by PharmaCadence Analytical Services, LLC; F.G. is employed by BRI a Frontage Company; O.L. and F.V. are employed by Merck & Co.; M.J.R. is employed by Gossmer Bio, Inc.; and Y.M. is employed by Boehringer Ingelheim Pharmaceuticals, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.